Medios AG raises its forecast for fiscal year 2017 due to the positive development in the first half-year

Medios AG / Key word(s): Change in Forecast/Half Year Results

10-Aug-2017 / 15:41 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.



Ad hoc Release

Medios AG raises its forecast for fiscal year 2017 due to the positive development in the first half-year

Berlin, 10 August 2017 - In the context of preparing the half-year financial statements, the Management Board of Medios AG today raised its forecast for fiscal year 2017. Based on preliminary figures (IFRS), the company increased its sales revenue from January to June by 59 percent to EUR 117 million (prior year EUR 73,6 million, Pro-Forma** IFRS) compared with the prior-year period. Earnings before taxes (EBT*) grew by 39 percent to EUR 3,9 million (prior year EUR 2,8 million, Pro-Forma** IFRS).

This means that Medios has already reached more than half of the amounts expected for the whole year. As a result, the Management Board raises the forecast for sales revenue from around EUR 200 million to EUR 230 million. The forecast for EBT* is raised from around EUR 7 million to a target range from EUR 7,0 to 7,5 million, which takes into account impacts from growth investments and non-predictable consequences of the prohibition of public tendering on cytostatic drugs through the German Act on Strengthening Pharmaceutical Supply in Statutory Health Insurance.

The full half-year financial report of Medios AG will be published in September 2017 at

* EBT is defined as net earnings before income taxes
** According to the securities prospectus dated 16 November 2016

Medios AG
Matthias Gärtner, CFO
Phone: +49 30 23256680

About Medios AG
Medios is one of the leading competency partners and solutions providers for specialty pharmaceuticals in Germany. These are medicines for patients with rare or chronic diseases such as cancer, HIV and hepatitis, whose personalized therapy is often tedious and cost-intensive due to their individual requirements.

With our subsidiaries Medios Pharma, Medios Manufaktur and Medios Digital we connect individual market players to form cooperating partners. Our goal is to provide partners and customers with integrated solutions along the value chain, ensuring optimal patient care.

Medios AG is Germany's first listed Specialty Pharma company. The share (WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the Frankfurt Stock Exchange (General Standard).

Press contact
Kirchhoff Consult AG
Nikolaus Hammerschmidt
Borselstraße 20
22765 Hamburg
Phone: +49 40 60918618
Fax: +49 40 60918660

This notification contains forward-looking statements that are subject to certain risks and uncertainties. Future results may significantly deviate from currently expected results, specifically due to various risk factors and uncertainties such as changes in business, economic, and competitive circumstances, exchange rate fluctuations, uncertainties about legal disputes or investigations, and the availability of financial resources. Medios AG assumes no responsibility whatsoever for updating the forward-looking statements contained in this notification.

10-Aug-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

Company:Medios AG
Friedrichstraße 113a
10117 Berlin
Phone:+49 30 232 566 - 800
Fax:030 / 8321 8377
Listed:Regulated Market in Frankfurt (General Standard), Hamburg; Regulated Unofficial Market in Dusseldorf

End of AnnouncementDGAP News Service


show this